Document:

Exhibit 10.10

 

 

INMET S.A.

 

Ocampo 210 bis

 

Predio CCT

 

Rosario, Santa Fe, Argentina

 

January 21, 2016

 

This Is to inform you that SenesTech Inc., with domicile at
3140 N. Caden Court, Suite 1, Flagstaff, Arizona, United States, accepts the Agency Agreement with INMET S.A., dated January 20,
2016.

 

	/s/ Loretta P. Mayer	 
	 	 
	For SenesTech Inc.	 
	 	 
	Name: Loretta P. Mayer	 
	 	 
	Title: CEO	 
	 	 
	Date: 01.21.2016	 

 

	SenesTech, Inc.	3140 N. Caden Ct., Suite 1, Flagstaff, AZ. 86004	928-779-4143

 

 

________________________

Confidential treatment has been requested for portions of
this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as
“xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 

     

     

    

 

City of Rosario, January 20, 2016

 

To

SenesTech Inc.

3140 N. Caden Court, Suite 1

Flagstaff, Arizona, United States

Attn. Tom Chesterman

 

Ref.: Offer - Agency

 

Dear Sirs,

 

INMET S.A. (“INMET”),
domiciled at Ocampo 210bis, Rosario, Provincia de Santa Fe (CP 2000), hereby represented by Federico Trucco, addresses this
letter to propose that SenesTech, Inc. (“SenesTech”), domiciled at 3140 N. Caden Court, Suite 1 Flagstaff,
Arizona, United States (jointly with INMET, the “Parties”) enter into an Agency Agreement (the
“Offer”), In case this Offer is accepted, the ensuing relationship between the Parties shall be governed by the
terms and conditions attached hereto as Annex 1

 

This Offer shall be deemed accepted if
you notify us of your acceptance in writing on or before January 21, 2016. If after said date we have not received your acceptance.
this Offer shall loose all force and effect.

 

Sincerely,

 

	INMET S.A.	 
	 	 
	/s/ Federico Trucco	 
	 	 
	Name: Federico Trucco	 
	 	 
	Title: Legal Representative	 

 

 

 

________________________

Confidential treatment has been requested for portions
of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated
as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 

     

     

    

 

ANNEX I

 

AGENCY AGREEMENT, dated as of January
21, 2016, the “Effective Date”, hereinafter the “Agreement”, by and between SenesTech a Delaware
corporation (“SenesTech”), and INMET S.A., a corporation incorporated under the laws of Argentina (“INMET”
or “Agent”).

 

WHEREAS, SenesTech
is a life science company that has developed a technology for managing animal pest populations through fertility control called
ContraPest (hereinafter the “Product”);

 

WHEREAS, INMET
is an industrial biotechnology company with expertise on the production and commercialization of industrial enzymes and fermentation
technologies;

 

WHEREAS, SenesTech
desires to register and sell the Product in the Territory and INMET desires to conduct the registration approval process and sell
the Product in the Territory on behalf of SenesTech;

 

WHEREAS, SenesTech
and INMET desire to establish the framework, terms and conditions upon which INMET will initially act as SenesTech’s agent
for the regulatory approval of the Product in the Territory, and ultimately act as SenesTech’s agent for the commercialization
of the Product in the Territory,

 

NOW, THEREFORE,
in, consideration of the premises and mutual representations, warranties and covenants herein contained, the parties hereby agree
as follows:

 

1.             Definitions

 

1.1           “Affiliate”
means any corporation, firm, limited liability company, partnership, or other entity that directly or indirectly controls, or is
controlled by, or is under common control with a Party to this Agreement. For the purpose of this definition, control means ownership,
directly or through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election
of directors in the case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any other type
of legal entity, or status as a general partner in any partnership, or any other arrangement whereby a Party controls or has the
right to control the board of directors or equivalent governing body of a corporation or other entity.

 

1.2           “Confidential
Information” means (i) any proprietary or confidential information or material, including all trade secrets, in tangible
form disclosed hereunder that is marked as “Confidential” at the time it is delivered to the receiving Party, or (ii)
proprietary or confidential information or material, including all trade secrets, disclosed orally hereunder that is identified
as confidential or proprietary When disclosed, provided however, that the above information shall not be deemed Confidential Information
to the extent the receiving Party can establish by competent written proof that such information:

 

1.2.1           was
already known to the receiving Party, other than under an obligation of confidentiality owed to the disclosing Party, at the time
of disclosure;

 

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 
	 	-2-	 

     

    

 

1.2.2           was
generally available to the public or otherwise part of the public domain at the time of its disclosure hereunder to the receiving
Party;

 

1.2.3           becomes
generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement or any other relevant confidentiality agreement;

 

1.2.4           is
independently developed by the receiving Party without reference to any Confidential Information disclosed by the disclosing Party;
or

 

1.2.5           was
subsequently disclosed to the receiving Party by a person other than the disclosing Party without breach of any legal obligation
to the disclosing Party.

 

1.3           “Product”
means the ContraPest product set forth on Exhibit A.

 

1.4           “Regulatory
Approval” means receipt of all necessary approvals from, the appropriate regulatory authorities whose purpose is to allow
for the commercial production, culture, importation or exportation, and sale of the Product in the jurisdiction governed by such
regulatory authority within the Territory,

 

1.5           “Regulatory
Submission” means a submission of a regulatory package, referring to the Product, to a regulatory authority whose purpose
is to allow for the commercial production, culture, importation or exportation, and sale of the Product for its intended use in
the jurisdiction governed by such regulatory authority. All regulatory submissions will be made by INMET on behalf of and in the
name of SenesTech.

 

1.6           “Territory”
means Argentina.

 

2.             Appointment.
SenesTech hereby appoints INMET to act as SenesTech’s agent for the Regulatory Approval and pre-sales marketing of the Product
in the Territory and during the Term of this Agreement. This appointment is on an exclusive basis as set forth in Section 3 below.

 

3.             Commercialization:
SenesTech and INMET agree to diligently pursue a definitive agreement to form a venture, in a corporate form to be determined,
for the manufacturing of the Product and the commercialization of the Product in Argentina and other countries as may be mutually
agreed, on general terms as attached hereto as Exhibit B.

 

4.             Exclusivity.
SenesTech agrees that it will not (directly or indirectly) market, offer for sale or sell any Product to any person or entity
(other than INMET) in the Territory during the Term of this Agreement.

 

5.             Diligence
obligations

 

5.1           INMET
Diligence Obligations. Subject to the terms and conditions set forth herein, INMET shall demonstrate commercially reasonable
diligence in obtaining regulatory approvals.

 

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 
	 	-3-	 

     

    

 

5.2.          General
Contribution of SeneTech. SeneTech will supply to INMET those materials, data, and scientific and regulatory support
necessary, so as to allow INMET to timely implement and perform its responsibilities under this Agreement

 

6.             Regulatory

 

6.1           Regulatory
Approval. INMET shall be responsible for timely preparing all necessary Regulatory Submissions and using commercially reasonable
efforts to obtain necessary Regulatory Approval to manufacture and commercialize Product within the Territory. All regulatory submissions
and licenses shall be in the name of SenesTech.

 

6.2           Access
to Regulatory Data. INMET and SenesTech will grant to each other access to all regulatory data within their control, including
any regulatory dossier that may be developed, for use under this Agreement should INMET or SenesTech find the same useful and make
a written request for the same. Without limiting the generality of the foregoing, INMET and SenesTech agree to coordinate their
regulatory efforts and share information with one another with respect

to the Product

 

6.3           Regulatory
Management and Regulatory Studies. Except as otherwise provided herein, any and all costs attributable to the Regulatory Approval
of the Product in the Territory, including third party costs incurred in connection with obtaining Regulatory Approvals for Product,
shall be borne by INMET. To the extent that Regulatory Approval of Product within the Territory is dependent in whole or in part
on Regulatory Approval of Product outside the Territory (and vice versa), INMET and SenesTech will coordinate their efforts in
pursuit of such Regulatory Approval(s) and will negotiate and agree upon equitable allocation between them of the costs associated
with obtaining such Regulatory Approval(s).

 

6.4.          Product
Stewardship and Monitoring. The Parties agree that there may be product stewardship and monitoring requirements associated
with obtaining a Regulatory Approval, and/or as a consequence of having received a Regulatory Approval. INMET in consultation with
SenesTech will be responsible for determining the nature of such product stewardship and monitoring requirements and for design
and implementation of such activities that may be necessary.

 

6.5.          Ownership
of Regulatory Data. Any all data relating to the Regulatory Approval of the Products within the Territory shall be owned by
and shall be considered Confidential Information of SenesTech (hereinafter “Regulatory Data”. INMET undertakes to execute
any documents necessary to give effect to this Section.

 

7.             Penalty

 

In consideration for conducting the Regulatory
Approval of the Product and in the event that Regulatory Approval is obtained or advanced significantly, and SenesTech unilaterally
decides not to pursue commercialization within the Territory, or unilaterally decides to pursue commercialization within the Territory
without the involvement of INMET as provided for in Exhibit B, SenesTech will pay to INMET XXXX.

 

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 
	 	-4-	 

     

    

 

8.             Warranties

 

8.1.          NO
WARRANTY. ANY AND ALL INFORMATION, TECHNOLOGY, AND MATERIALS PROVIDED UNDER THIS AGREEMENT ARE PROVIDED “AS IS.”
EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NO WARRANTIES, EXPRESS OR IMPLIED, ARE MADE BY ANY PARTY UNDER THIS
AGREEMENT, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR PURPOSE.

 

8.2           LIMITATION
OF LIABILITY. EXCEPT IN THE CASE OF WILLFUL MISCONDUCT OR GROSS NEGLIGENCE, NEITHER PARTY SHALL BE LIABLE IN CONTRACT, TORT, OR
OTHERWISE TO THE OTHER, OR ANY THIRD PARTY FOR SPECIAL, INCIDENTAL, INDIRECT OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION,
LOSS OF USE, LOSS OF DATA, OR LOSS OF PROFITS OR REVENUE ARISING FROM ANY CAUSE WHATSOEVER, REGARDLESS OF WHETHER IT SHALL BE ADVISED,
SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY.

 

9.             Indemnification.

 

(a)          INMET
will indemnify, defend and hold harmless SenesTech and its officers, directors, employees, stockholders, agents,
representatives, subsidiaries, parents and affiliates from all claims, damages, assessments, costs, losses and other
expenses, including but not limited to reasonable attorneys’ fees and costs arising out of or resulting from any claim,
demand, suit, action or other proceeding (collectively, “Claims”) to the extent that such Claim arises out
of: (a) INMET’s breach of this Agreement, (b) any negligent act or omission of INMET, or (c) any Claim by any customer
of INMET or any other third party related to the manufacture, use, distribution or sale of Product purchased hereunder.

 

(b)          SenesTech
will indemnify, defend and hold harmless INMET and its officers, directors, employees, stockholders, agents, representatives, subsidiaries,
parents and affiliates from all claims, damages, assessments, costs, losses and other expenses, including but not limited to reasonable
attorneys’ fees and costs arising out of or resulting from any Claims to the extent that such Claim arises out of: (a) SenesTech’s
breach of this Agreement, or (b) any negligent act or omission of SenesTech.

 

10.           Confidentiailty

 

10.1.          Confidential
Information. Except as expressly provided in this Agreement, the Parties agree that, for the Term and for five (5) years thereafter
or as long as trade secret law shall allow, whichever is longer, the receiving Party shall keep completely confidential and shall
not publish or otherwise disclose and shall not use for any purpose except for the purposes contemplated by this Agreement any
Confidential Information furnished to it by or otherwise obtained from the disclosing Party pursuant to this Agreement. Without
limiting any provision of this Agreement, each of the Parties hereto shall be ressponsible for the observance by its employees
of the confidentiality obligations set forth in this Agreement.

 

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 
	 	-5-	 

     

    

 

10.2.          Permitted
Disclosures. Except as otherwise limited by this Agreement, each Party may disclose the other Party’s Confidential Information
and scientific data resulting from the activities conducted under this Agreement only (a) to its Affiliates, or to its advisors,
financial investors, including prospective financial investors, and the agents or advisors of the foregoing and other similarly
situated third parties on a need-to-know basis, if such Affiliates, and other permitted recipients agree to be bound by the terms
of this Section 10 or have a fiduciary duty of confidentiality, and (b) to the extent such disclosure is reasonably necessary
in connection with, prosecuting or defending litigation, complying with applicable governmental regulations, submitting information
to tax or other governmental authorities, making a permitted sublicense or otherwise exercising its rights hereunder, provided
that if a Party is required to make any such disclosure of another Party’s Confidential Information, other than pursuant
to a confidentiality agreement, it shall give reasonable advance notice to the latter Party of such disclosure and, to the extent
permitted by law or regulations, shall cooperate with the original disclosing Party in any effort by the original disclosing Party
to secure a protective order blocking the disclosure of, or otherwise affording confidential treatment to, such Confidential Information.

 

11.           Term
and Termination.

 

(a)          Term.
The term of this Agreement will start on the Effective Date and will expire the earlier of: (a) when the Parties incorporate a
new company based on Argentina pursuant to the terms laid out in Exhibit B, or (b) one year.

 

(b)          Termination
for Cause. Either party may terminate this Agreement: (i) upon the other party ceasing to conduct business, becoming or being
declared by a federal bankruptcy court to be insolvent or bankrupt, or being the subject of any proceeding under the federal
bankruptcy code relating to its insolvency that is not dismissed within 60 days; (ii) upon the appointment of a receiver for all
or any portion of the other party’s business or operations; (iii) upon the assignment of all or substantially all the assets
of the other party for the benefit of creditors; or (iv) upon the other party’s material breach of this Agreement, if the
other party fails to cure such breach within 30 days after receipt of written notice specifying the breach in reasonable detail.

 

(c)          Survival.  
The following Sections will survive termination of this Agreement: 7, 8, 9, 10, 11, 12(c), 12(d) and 13.

 

12.           Miscellaneous.

 

(a)          This
Agreement (i) constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral,
among the parties with respect to the subject matter hereof and (ii) may not be assigned by operation of law or otherwise: provided,
that, either party may assign this Agreement to the surviving entity in the event of a merger, acquisition or sale of all or substantially
all of the assets of such party. INMET hereby consents to the assignment by SenesTech of its rights and obligation under this
Agreement to any subsidiary of SenesTech.

 

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 
	 	-6-	 

     

    

 

(b)          Nonperformance
of either party, except nonperformance of payment obligations, will be excused to the extent that performance is rendered impossible
by any Act of God or circumstances beyond the control of a party and without its fault or negligence, including without limitation,
fire, war, riots, flood, earthquake, failure of third party hardware or software, governmental acts or orders or restrictions,
or power or communications failure (a “Force Majeure Event”), provided that the non-performing party gives
prompt notice of such Force Majeure Event to the other party and makes all commercially reasonable efforts to remove such causes
of non performance promptly and perform whenever such Force Majeure Event has ceased. In the event that the Force Majeure Event
continues for greater than ninety days, either party may terminate this Agreement upon written notice to the other party, and
upon such termination, neither party shall have any further obligation or liability to the other except as set forth in Section
7.

 

(c)          All
notices and other communications hereunder: (i) shall be in writing, (it) shall be first given via email at the email address set
forth below (or at such other email address for a party as shall be specified by like notice), and (iii) shall be deemed given
if delivered by hand or sent via a reputable international overnight courier service to a party at the address of such party set
forth below (or at such other address for a party as shall be specified by like notice) and shall be deemed given on the date on
which so hand-delivered or on the business day following the date on which so sent.

 

	If to SenesTech;	If to INMET:
	 	 
	SenesTech, Inc.	INMBT S.A.
	Attn: Thomas C. Chesterman, CFO	Attn: Gustavo Schujman
	3140
    N. Caden Court, Suite 1	Ocampo 210 Bis
	Flagstaff,	Rosario (2000)
	Arizona, United States	Argentina
	 	Email:
	 	Gustave.schujman@indear.com.ar

 

(d)          Any
provision of this Agreement that is prohibited or unenforceable in any jurisdiction will, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition
or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

(e)          INMET
will have no authority to bind or otherwise obligate SenesTech in any manner nor shall INMET represent to anyone that it has a
right to do so.

 

(f)          The
parties hereto acknowledge that damages alone may not adequately compensate a party for violation by another party of this Agreement.
Accordingly, in addition to all other remedies that may be available hereunder or under applicable law, any party shall have the
right to any equitable relief that may be appropriate to remedy a breach or threatened breach by any other party hereunder, including
the right to enforce specifically the terms of this Agreement by obtaining injunctive relief in respect of any violation or non-performance
hereof.

 

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 
	 	-7-	 

     

    

 

(g)          This
Agreement will be deemed to be made in and in all respects will be interpreted, construed and governed by and in accordance with
the law of the State of Delaware without regard to any applicable principles of conflicts of law. Any dispute arising between the
Parties in connection with construing and performance or non performance of the present Agreement shall be referred, failing agreement
between the Paities, to the competent court of the state of Delaware.

 

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 
	 	-8-	 

     

    

 

EXHIBIT A

CONTRAPEST

 

[EPA’s application]

 

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 
	 	-9-	 

     

    

 

EXHIBIT B

 

Argentinean share corporation focused on the manufacturing of
ContraPest (hereinafter NewCo)

 

		a.	Currently favoring a share corporation structure, such
as a Sociedad Anonirma.

		b.	To be located in Rosario, to service the Argentinean and
nearby markets

		c.	51% voting control to SenesTech

		d.	xxxx of economics to BC via a Shareholder Agreement or different share classes/preferences
                                                                                 whereby Bioceres receives xxxx and to xxxx;

		e.	NewCo to be an exclusive licensee of SenesTech (as an affiliate),
and SenesTech’s exclusive distributions within the Territory;

		f.	SenesTech would be responsible for the assembly of a production
facility for the manufacture of the Product in the Territory, at Bioceres cost and in Bioceres’ facilities.

		g.	SenesTech would provide training and production process
supervision including Quality Control supervising as it is presented at EPA in the USA; BC would provide operating personnel and
supply responsibilities.

		h.	While focused initially in the Territory, SenesTech would
buy from NewCo for other markets where cost effective

		i.	NewCo will have preferential terms for the supply of components
and other materials required for Product manufacturing

 

This structure may be duplicated in other areas where Bioceres
has operations in the future

 

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

 
	 	-10-Exhibit
10.11

 

SERVICES
AGREEMENT

 

The
present SERVICES AGREEMENT (hereinafter the “Agreement”) is made effective as of this day of January 21, 2016 (the
“Effective Date”), by and between SenesTech, Inc, 3140 N, Caden Court, Suite 1 Flagstaff, Arizona, United States
(hereinafter “SenesTech”); Bioceres, Inc., a Delaware corporation and wholly-owned subsidiary of Bioceres S.A.
with offices at Ocampo 210 Bis, Predio CCT, Rosario (2000), Argentina (hereinafter “Bioceres”) and INMETS.A.,
an Argentinean corporation with a registered office at Ocampo 210 bis, Rosario, Santa Fe, Argentina, (hereinafter “INMET)
and jointly with SenesTech the Service Providers (hereinafter “Providers”).

 

SenesTech,
Bioceres and Providers shall individually or collectively be referred to as a “Party” or the “Parties”.

 

WHEREAS,
SenesTech is a life science company that has developed a technology for managing animal pest populations through fertility control.

 

WHEREAS,
Bioceres is a fully-integrated agricultural technology company with a strong leadership position in South America.

 

WHEREAS,
INMET is a industrial biotechnology company with expertise on the production of industrial enzymes and fermentation technologies;

 

WHEREAS,
SenesTech and Bioceres wish Providers to conduct services including but not limited to research and development activities designed
to obtain an efficient production method for synthetic triptolide based on metabolic engineering of Bacillus subtilis strains,
as described in Exhibit B herein;

 

WHEREAS,
SenesTech and Bioceres desire to establish one or more strategic business relationships between them and to enter into a business
relationship under the form of a joint venture company for the development and commercialization of synthetic triptolide (hereinafter
the “NewCo”).

 

WHEREAS,
in accordance with the business of the NewCo, SenesTech and Bioceres undertake that the services provided under this Agreement
could be funded as contributed services by SenesTech and Bioceres for the benefit of the NewCo, and

 

NOW,
THEREFORE, for and in consideration of the promises and other obligations reflected herein, the Parties agree as follows:

 

Article
1. Definition

 

The
following capitalized terms shall have the meaning ascribed to them below:

 

By
“Affiliates”, the Parties mean any corporation or other entity which directly or indirectly:

 

		(a)	Controls;

 

		(b)	is Controlled by; or

 

		(c)	is under the common Control of the Controller of, such
Party.

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	1

     

    

  

In
this definition, “Control” (including its cognates such as “Controlling” or “Controls” or
“Controller”) means in respect of any Person the ownership directly or through one or more intermediate entities
of 50% or more of the voting shares in a company or, in respect of any other legal entity, ownership of 50% or more of the
equity in the legal entity or the ability, directly or through one or more intermediate entities, to director cause the
direction of the management and policies of such Person including without limitation the ability to select 50% or more of the
board of directors of such Person (or functionally similar group). A group of Persons shall be deemed to Control another
Person if (a) such group collectively has rights that if held by a single Person would constitute Control of such other
Person hereunder; and (b) the Persons in such group have agreed to coordinate their behavior by contract with respect to the
exercise of such rights.

 

By
“SenesTech Material”, the Parties mean the material listed in Exhibit A hereinafter enclosed, any and all mutants, constituents,
progeny and derivatives of such materials (including, but not limited to, substances that constitute a functional subunit of or
product expressed by the materials, such as subclones, protein expressed from DNA, RNA, or corresponding sequence information,
cell lines, plants, seeds, and parts thereof expressing such materials) and related proprietary information, to be provided by
SenesTech and/or its affiliates to Providers for the sole purpose of Providers performing the Services, in accordance with and
pursuant to this Agreement.

 

By
“Facility” the Parties mean the Providers’ facilities located at Ocampo 210 bis, Rosario, Argentina; and the other trial
facilities where the Providers and Providers’ subsidiary, contractor or employee shall perform the Services;

 

By
“Intellectual Property Rights, the Parties mean all intellectual property including but not limited to:

 

(a)          patents,
pending applications for patents, and rights to applyforpatents in anypart of the world;

(b)          copyrights,
design rights, Internet domain names, anddatabase rights, whetherregistered or unregistered, and software;

(c)          pending
trademark and service mark applications, registered trademarks and service marks, registered designations of origin, unregistered
trademarks and service marks, including common law trademarks and service marks, rights to trade dress and company names, and in
each case with any and all associated goodwill;

(e)          genetic
material;

(f)          inventions
and related improvements, if any, processes, designs, formulae, trade secrets, know-how, industrial models, confidential technical
and business information, manufacturing, engineering and technical drawings, and product specifications, if any;

(g)          reissues,
divisions, continuations, continuations-in-part, renewals, extensions and registrations or foreign counterparts of any of the foregoing;
and

(h)          rights
to claim priority, reciprocity, or national treatment.

 

By
“Person”, the Parties mean an individual, corporation, partnership, trust, limited liability company or other entity,
including without limitation a governmental authority.

 

By
“Results”, the Parties mean the results of the research and development Services, including all deliverables, improvements,
discoveries, development, original works of authorship, trade secrets, information, material, know-how, results, inventions, and/or
other matter capable of being the subject of Intellectual Property Rights, whether or not patentable, which is conceived, first
reduced to practice or writing, and/or developed in whole or substantial part in the course of the Services and in performing under
the Work Plan, all of which will be jointly owned by SenesTech and Bioceres or the NewCo.

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	2

     

    

 

 

By
“Services”, the Parties mean the services to be provided by Providers under this Agreement, which consist in performing
research and development activities designed to obtain an efficient production method for synthetic triptolide based on metabolic
engineering of Bacillus subtilis strains, as, as further defined in the present Agreement and in more detail the Work Plan;

 

By
“Third Party”, the Parties mean any individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint
venture or other similar entity or organization, other than SenesTech, SenesTech’s Affiliates, Bioceres, Bioceres’ Affilliate
or Providers or Providers’ Affiliates.

 

By
“Work Plan” means the research and development plan established by the Parties and attached to this Agreement as Exhibit
B.

 

The
following definitions apply unless the context requires otherwise:

		(a)	the singular includes the plural and conversely;

		(b)	headings are for convenience only and do not affect
interpretation;

		(c)	a gender includes all genders;

		(d)	if a word or phrase is defined, its other grammatical
forms have a corresponding meaning.

 

Article 2. Conditions for the
supply of the Material

 

SenesTech
will provide INMET with the SenesTech Material and INMET shall use the SenesTech Material in strict compliance with the
following terms and conditions:

 

		2.1	INMET shall use the SenesTech Material solely for the purpose of conducting the Services, and as
defined under the Work Plan.

 

		2.2	The transfer of the SenesTech Material to INMET shall not
in itself constitute any grant, option or license to Providers under any patent, trade secret or other rights now or hereinafter
held by or under the control of SenesTech other than the non-exclusive, non-transferable, revocable right to use the SenesTech
Material to perform the Services. Risk of loss of the SenesTech Material shall be transferred to INMET upon reception of the SenesTech
Material to the Facility.

 

		2.3	INMET shall use the SenesTech Material in compliance with
all applicable laws and regulations INMET acknowledges that it is fully aware of the nature of the Material and assumes full
responsibility for performing its tasks under this Agreement in accordance with any and all laws and regulations applicable at
the Facility.

 

		2.4	INMET shall not reverse-engineer, transfer, sell, assign or otherwise dispose of the SenesTech
Material, including parts or sequences thereof, without the prior written agreement of SenesTech.

 

		2.5	The SenesTech Material, the genetic characteristics of such SenesTech Material shall be used only
by the personnel of INMET, or INMET’s subsidiary, contractor or employee, who has a need to use the SenesTech Material, for
the purpose of performing the Services and shall not be provided to any Third Party. INMET further agrees to use all best efforts
to ensure adequate security measures are in place to protect the SenesTech Material against any Third Party’s access. The
SenesTech Material shall be used in the Facility only and shall not be transferred outside the Providers’s Facility without
the prior written approval of SenesTech.

 

		2.6	INMET shall bind any INMET’s subsidiary, contractor or employee to comply with terms at least
as stringent as the terms herein and shall be duly responsible for its INMET’s subsidiary, contractor or employee compliance /
non-compliance with the terms herein.

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	3

     

    

 

Article 3. Services.

 

		3.1	Performance of Services. Providers will provide the Services
to SenesTech and Bioceres as described in detail in the Work Plan.,

 

		3.2	Work Plan. The Work Plan as established by the Parties is attached hereto as Exhibit B. In general,
the Work Plan provides;

 

3.2.1         a
description of the Services performed by Providers in sufficient detail to enable a reasonable determination of the value of such
Services in accordance with Article 7 of this Agreement;

 

3.2.2         the
approximate date upon which such Services are estimated to be initiated and completed;

 

3.2.3         when
its deliverables are completed according to the Services; and

 

3.2.4         any
other terms and conditions agreed upon by the Parties.

 

Article 4. Licenses -
Ownership of Results

 

		4.1.	SenesTech and its Affiliate and Bioceres’ and its Affiliate will each grant a non-royalty-bearing
license to Providers to its Intellectual Property as may be required to fulfill the Services within the Territory on a non-exclusive
basis, PROVIDED however that such Intellectual Property, shall remain the property of each Party.

 

		4.2.	The Parties agree that the Results
                                         will be jointly owned by SenesTech and Bioceres, or NewCo. Providers hereby irrevocably
                                         assign, and shall ensure that any member of its staff assigns (if applicable), all Intellectual
                                         Property Rights in such Results for the entire duration of such Intellectual Property
                                         Rights. Compensation for the assignment of the intellectual Property Rights is included
                                         in the financial compensation paid by SenesTech and Bioceres in Article 7.

 

		4.3.	Providers shall not make or
apply for, directly or indirectly, any Intellectual Property
Rights relating to or in connection with the Results, Providers shall communicate to SenesTech and Bioceres the Results,
on a regular basis or upon SenesTech’s and Bioceres’s request or in accordance with any schedule agreed to between the Parties
in the Exhibit B hereto. Providers shall communicate to SenesTech and Bioceres all the information and other elements, technical
or administrative, that SenesTech and Bioceres may reasonably require for any Intellectual Property Rights in relation to the Results.

 

Article 5. Duration

 

The
present Agreement shall enter into force as from the Effective Date and remain effective for a period of two years (the “Term”).
The Term may be extended upon mutual agreement of the Parties as evidenced in a written amendment to that effect.

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	4

     

    

 

Article 6. Obligation
to provide information

 

On
a confidential basis and upon reasonable written request of SenesTech and Bioceres, Providers shall inform SenesTech and Bioceres
on (i) the progress of the Services, (ii) each; Result obtained, once per calendar quarter and at the end of the Services, Providers
will make a confidential written report to SenesTech and Bioceres with detailed information on each Result obtained.

 

Article
7. Financial Compensation

 

		7.1	In consideration for the due and proper performance of the Services by Providers, SenesTech and
Bioceres undertake to pay the total cost of the budgeted activities as detailed in Exhibit B, proportionately to Ownership in NewCo.
First payment will not be due until the base genetic SenesTech Material is available to begin Services.

 

Any
additional fees will need to be pre-approved in writing by SenesTech and Bioceres.

 

		7.2	Services shall be compensated on a monthly basis, in advance, based on an approved budget.

 

Article
8. Undertakings, Representations and Warranties

 

		8.1	Any SenesTech Material is provided “as-is” and Providers, SenesTech and Bioceres makes
no warranties of any kind, either express or implied, including but not limited to warranties of merchantability, fitness for a
particular purpose. In no event shall a Party be liable for incidental or consequential damages of any kind, including economic
damage or injury to property and lost profits, regardless of whether the other Party shall be advised, shall have other reason
to know, or in fact shall know of the possibility of the foregoing.

 

		8.2	Providers agrees to perform the Services for the exclusive benefit of SenesTech and Bioceres, or
NewCo, in a highly professional and ethical manner. Providers undertake to comply with all applicable laws, regulations and professional
standards. Providers certifies and warrants it has obtained and will maintain all necessary authorizations and has proceeded
to any mandatory declaration and to proceed forthwith with the payment of any taxes, duties, levies, social insurance, and of any
other contributions which may be levied, payable or, as may be required by applicable laws and regulations and in relation to the
performance of the Services.

 

		8.3	Providers represents warrants and covenants that it has full power and authority to enter into
and perform the Agreement and that, as of the date of signature of the Agreement, it is not bound by any obligation or commitment
with a Third Party that could conflict with the terms of the Agreement or otherwise impact the arrangement set forth herein in
this Agreement.

 

		8.4	SenesTech represents warrants and covenants that it has full power and authority to enter into
and perform the Agreement and that, as of the date of signature of the Agreement, it is not bound by any obligation or commitment
with a Third Party that could conflict with the terms of the Agreement or otherwise impact the arrangement set forth herein in
this Agreement.

 

		8.5.	Bioceres represents warrants and covenants that it has
full power and authority to enter into and perform the Agreement and that, as of the date of signature of the Agreement, it is
not bound by any obligation or commitment with a Third Party that could conflict with the terms of the Agreement or otherwise
impact the arrangement set forth herein in this Agreement.

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	5

     

    

  

		8.6	Providers warrants that the Results delivered to SenesTech and Bioceres within the frame of the
Services will be free from any liens, claims and encumbrances.

 

Article 9. Dispatching
of the Material

 

At
the receipt by SenesTech of a signed original of this Agreement, SenesTech shall send the SenesTech Material to Providers, at the
Providers’ Facility.

 

Any
SenesTech Material under this Agreement shall be sent free of charge by SenesTech to Providers’ Facility and if returned,
shall be returned at Providers’ sole costs and responsibility.

 

Providers
undertakes to provide SenesTech with all reasonable assistance as may be necessary for SenesTech to apply for and/or obtain any
and all governmental or other authorizations, licenses and/or permits required for the delivery of the SenesTech Material to Providers
pursuant to this Agreement.

 

Article 10. Confidentiality

 

		10.1	During the term of this Agreement and for a period of five (5) years after its termination or expiration,
Providers undertakes to keep strictly confidential and not to publish or disclose to a Third Party, all the information which is
transmitted visually, orally, in writing, in electronically, or in any and all other manner by and proprietary to SenesTech, Bioceres
and/or its Affiliates pursuant to and in accordance with this Agreement, and/or relating to this Agreement, the SenesTech Material,
the Services and the Results (the “Confidential Information”) without the prior written consent of SenesTech
and Bioceres. Nothing herein shall be construed as a restriction for a Party to disclose its own proprietary confidential information.

 

		10.2	Providers shall only be entitled to disclose, on a need to know basis for the purpose of the Services,
Confidential Information to its directors or employees, (collectively the “Authorized Recipients”); provided that Providers
has previously bound such Authorized Recipients by confidentiality and restricted use obligations at least as stringent than those
set forth in this Agreement. Providers shall be responsible towards SenesTech and Bioceres for any breach by its Authorized Recipients
of any such confidentiality and restricted use obligations.

 

		10.3	Notwithstanding Article 10.1, Providers may use or disclose those information to the extend it
can demonstrate, by clear and convincing evidence, that such information:

 

		(a)	at the time of disclosure or acquisition is generally available to the public, or after the time
of disclosure or acquisition is generally available to the public through no wrongful act or omission of Providers and its Authorized
Recipients, or

 

		(b)	was in the lawful possession and at the free disposal of Providers prior to disclosure by SenesTech
and/or Bioceres, as evidenced by written records then in the possession of Providers, or

 

		(c)	is rightfully made available Providers by a Third Party not bound by confidentiality or restricted
use obligations, or

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	6

     

    

  

		(d)	is independently developed by Providers without use of the SenesTech Material and information imparted
by SenesTech, or

 

		(e)	is disclosed by Providers in order to comply with the requirements of applicable law, governmental
regulation or definitive court order, provided that Providers shall first notify SenesTech and Bioceres of such required disclosure
and of each Confidential Information concerned and shall limit such disclosure as far as possible under applicable law. Such disclosure
shall, however, not relieve Providers of its other obligations contained herein.

 

		10.4	Providers agrees not to publish any Result without prior written consent from SenesTech and Bioceres.

 

Article 11. Termination

 

		11.1	SenesTech and Bioceres may terminate this Agreement at any moment and for any reason by giving
written notice to Providers.

 

		11.2	Upon termination or expiration of this Agreement, Providers’ right to use the SenesTech Material
and the Results shall cease. Any SenesTech Material, Results remaining in the possession of Providers at such date will be destroyed
or returned to SenesTech, Bioceres or to NewCo (at SenesTech and Bioceres’ decision) promptly upon the request of SenesTech,
Bioceres or to NewCo.

 

		11.3	The termination by SenesTech and by Bioceres to the Agreement does not restrict in any manner the
duties or liabilities incurred or contracted by SenesTech and by Bioceres that, at the time of such termination, has already accrued
to INMET.

 

		11.4	No termination or expiration of this Agreement shall relieve either Party of its obligations set
forth in 4, 7, 8, 10, 11, and 12 and such sections shall survive.

 

Article 12. Governing law

 

The
present Agreement is governed by the laws of the state of Delaware without giving effect to the principles of conflicts of laws.

 

Any
dispute arising between the Parties in connection with construing and performance or non Performance of the present
Agreement shall be referred, failing agreement between the Parties, to the competent court of the state of Delaware.

 

Article 13. Miscellaneous

 

		13.1	Exhibit(s) hereinafter enclosed form an integral part of this Agreement and are hereby incorporated
in the Agreement.

 

		13.2	This Agreement (a) may not be assigned or transferred by Providers without the prior written consent
of SenesTech and Bioceres, (b) may not altered amended, or modified in whole or in part, except by prior written agreement signed
by the Parties. However, this Agreement contemplated that shall be contributed by SenesTech and Bioceres to Newco when is established.

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	7

     

    

  

		13.3	If any provision or provisions of this Agreement shall be held to be invalid, illegal, or unenforceable,
the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

		13.4	Failure to enforce any provision of this Agreement does not constitute waiver of any term hereof.

 

		13.5	Force Majeure. Each Party shall be excused from any breach of this Agreement that is caused by
a change of government regulation, war, strike, act of nature, or other similar circumstance deemed outside the reasonable control
of such Party (“Force Majeure Event”). A Party claiming to be unable to perform its obligations under this Agreement
shall promptly inform the other Party (the “Non-Prevented Party”) of the occurrence, nature, extent, effect and likely
duration of such Force Majeure Event, and shall use all reasonable endeavors to minimize the effect of such event on the performance
of its obligations under this Agreement and shall forthwith after the cessation of the event, notify the other Party thereof and
resume full performance of its obligations under this Agreement. If the Force Majeure Event continues or is expected to continue
for more than thirty (30) days from the date of the notification as mentioned above, the Parties shall consult each other in order
to find a mutually acceptable solution for the continuation of the Agreement, during and following the cessation of the Force Majeure
Event. If the Parties fail to reach an agreement following the good faith negotiation; then this Agreement shall be terminated
upon prior written notice given by the Non-Prevented Party.

 

		13.6	Any notice of communication to be given hereunder or for the purpose hereof shall be duly given
by either Party if sent by prepaid registered post or by any other method of delivery capable of providing reasonable proof of
receipt thereof and sent to the other Party hereto, as follow:

 

	If to SenesTech:	 	If to Providers:
	 	 	 
	SenesTech, Inc.	 	INMET S.A.
	Attn: Loretta P. Mayer	 	Attn: Gustavo Schujman
	3140 N. Caden Court, Suite 1	 	Ocampo 210 Bis
	Flagstaff, Arizona, United States	 	Rosario (2000) 

Argentina
	 	 	 
	If to Bioceres:	 	 
	
        Bioceres
        Inc. wholly-owned subsidiary of

        Bioceres S.A.

        Attn:
        Federico Trucco

        Ocampo 210 Bis

        Rosario (2000)

        Argentina
	 	 
	 	 	
        SenesTech,
        Inc.

        Attn:
        Cheryl Dyer

        3140
        N. Caden Court, Suite 1

        Flagstaff,
        Arizona, United States

 

		13.7	This Agreement may be executed simultaneously in four counterparts, each of which shall be deemed
an original.

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	8

     

    

  

		13.8	In the event of any inconsistent or incompatible provisions,
the present document shall take precedence, followed by the Exhibits to this Agreement. Any provision(s) of an exhibit or annexures
to the present document, which object is to exclude or otherwise limit the responsibility of a Party beyond the provisions of the
present Agreement shall be null and void.

 

IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as of the day
and year written above.

 

	For
    Inmet	 	For
    SenesTech, Inc.
	 	 	 
	By:	/s/  Federico Trucco	 	By	/s/ Loretta
    P. Mayer
	Name:
    Federico Trucco	 	Name:
    Loretta P. Mayer
	Title:
    Legal Representative	 	Title:
    CEO

 

	For
    Biocares Inc.	 
	 	 
	By:	/s/ Federico
    Trucco	 
	Name:
    Federico Trucco	 
	Title:
    President & CEO	 

 

	 	For
    SenesTech,
    Inc. (as Providers)
	 	 	 
	 	By:	/s/
    Cheryl Dyer
	 	Name:
    Cheryl Dyer
	 	Title:
    Chief Research Officer

    

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	9

     

    

  

Exhibit A

 

SenesTech Material

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	10

     

    

 

Exhibit
B

 

Work
Plan & Budget

 

Providers
shall perform the following Services:

 

		1.	INMET

 

	Activity	xxxx	xxxx	Deliverable
	A.
    Pathway identification	 	 	 	 	 	 	 	 	 
	A.1.Transcriptome
    mining	 	 	 	 	 	 	 	 	Candidate
    gene list
	A.2.
    Complete cDNA obtainment	 	 	 	 	 	 	 	 	Gene
    sequences
	B.
    Strain construction	 	 	 	 	 	 	 	 	 
	B.1.
    xxxx pathway genes design & synthesis	 	 	 	 	 	 	 	 	Synthetic
    genes
	B.2.
    Triptolide pathway genes design & synthesis	 	 	 	 	 	 	 	 	Synthetic
    genes
	B.3.
    Gene cloning	 	 	 	 	 	 	 	 	Plasmid
    library
	B.4.
    Construction of strains	 	 	 	 	 	 	 	 	Strain
    collection
	C.
    Product characterization	 	 	 	 	 	 	 	 	 
	C.1.
Characterization of xxxx	 	 	 	 	 	 	 	 	Chemical
    structure data
	C.2.
Quantification of xxxx	 	 	 	 	 	 	 	 	Production
    yield
	D.
    Strain optimization	 	 	 	 	 	 	 	 	 
	D.1.
    Metabolic profile of producer strain	 	 	 	 	 	 	 	 	 
	D.2.
    Knock-down of selected pathways	 	 	 	 	 	 	 	 	Improved
    strains
	D.3.
    Overexpression of selected pathways	 	 	 	 	 	 	 	 	Optimized
    strains
	E.
    Triptolide Purification	 	 	 	 	 	 	 	 	Pure
    triptolide at laboratory scale
	F.
    Scale up	 	 	 	 	 	 	 	 	Pure
    triptolide at pilot scale

 

INMET
to perform the services according to industry-accepted standards

 

Budget

 

Tentative
costs are indicated in ’000 U$S dollars.

 

	Services
    & consumables	 	 	 
	 	 	 	 
	Bioinformatics	XXXX	Synthetic
    genes	XXXX
	cDNA
    filling	XXXX	Molecular
    biology kits & reagents	XXXX

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	11

     

    

  

	Disposable material	XXXX
	General reagents	XXXX
	RMN analysis	XXXX
	HPLC-MS/MS analysis	XXXX
	GC-MS analysis	XXXX
	Solvents	XXXX
	Lab fermentation	XXXX
	Scale up	XXXX
	Replacements & equipment maint.	XXXX
	Small lab equipment	XXXX

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.
 

	 	2

     

    

  

FIRST
DRAFT -  CONFIDENTIAL

 

	Subtotal	XXXX

 

Human
resources + overhead

 

Three technicians at full dedication; two platform managers
and one lab manager at 50% dedication; unit manager at 15% dedication. Subtotal: XXXX

 

Total
budget: 720.

 

2. SenesTech

 

BIOASSAYS for TRIPTOLIDE POTENCY

 

For each sample or batch to be tested there is a graded increase
in effort, money and time to ascertain potency or efficacy that is essential for ContraPest to work and have market value

 

		1.	Run high pressure liquid chromatography (HPLC) analysis
of triptolide content

		a.	If purity is less than 90% run simple organic extractions, chloroform-methanol or ethyl acetate extractions

		b.	Dry off organic solvents and reconstitute to reanalyze on HPLC, must be greater than 90% pure

 

		2.	Make ContraPest bait with candidate triptolide and
conduct rapid screen for triptolide effect on male rat testes weight

		a.	In developing ContraPest we discovered that male rats are very sensitive to dosing so that within
xxxx of bait takes the testes weight is significantly xxxx

		b.	Provide ContraPest to adult male rats for xxxx, morning of xxxx euthanize rats, weigh testes, epididymis
and body and express as testis and epididymis index

 

		3.	Before scaling up a fermentation and/or purchasing
kilogram quantities from a triptolide source, conduct a feed and breed assessment

		a.	Provide bait for xxxx prebait and xxxx CP bait, put mating pairs together for xxxx and observe female rats for
another xxxx to determine if pregnant and/or give birth

		b.	Once females and males are separated, euthanize the males and determine testis, epididymis indices

		c.	Any pups bom will be euthanized at post natal xxxx

		d.	End of experiment euthanize the females, collect ovaries, fix and bank tissue

 

Assessment 1: cost $200 for duplicate measurements,
time 2-3 days

Assessment 2:
cost $750 per group of 4 male rats housed for 20 days (retired breeders, per diem, ContraPest bait, necropsy), time 2-3 weeks

Assessment 3: cost $2200 per group of 8 rats, 4 of each sex,
for 65 days, due to experiment being 3 times longer than assessment 2 and more hands on procedures during necropsy, time 2 months

 

 

    
________________________
Confidential treatment has been requested for portions of this agreement. This agreement omits the information subject to the confidential treatment request. Omissions are designated as “xxxx”. A complete version of this agreement has been submitted separately to the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]